FDA Approves Tremfya for Ulcerative Colitis
By Lori Solomon HealthDay Reporter
MONDAY, Sept. 16, 2024 -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis.
Tremfya is the first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis. It is approved for administration as a 200-mg induction dose intravenously at weeks 0, 4, and 8 by a health care professional.
The approval is based on results from the phase 2b/3 QUASAR study. Half of patients receiving Tremfya 200 mg subcutaneous (SC) maintenance every four weeks and 45 percent of patients receiving Tremfya 100 mg SC every eight weeks achieved the primary end point of clinical remission at week 44 versus 19 percent of patients receiving placebo. At one year, 34 percent (200 mg) and 35 percent (100 mg) of patients achieved endoscopic remission compared with15 percent receiving placebo.
"Treatment with Tremfya resulted in significant improvement in the chronic symptoms of ulcerative colitis, and importantly, normalization in the endoscopic appearance of the intestinal lining," David T. Rubin, M.D., from the University of Chicago Medicine and lead investigator for the QUASAR program, said in a statement.
Approval of Tremfya was granted to Johnson & Johnson.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Most TikTok Videos on Inflammatory Bowel Disease Are Low Quality
FRIDAY, June 13, 2025 -- The most-viewed inflammatory bowel disease (IBD) videos on TikTok provide low-quality medical information, according to a study published online in...
Chronic Conditions and Their Age of Onset Predict Health Trajectory in IBD
MONDAY, March 24, 2025 -- Among people with inflammatory bowel disease (IBD), conditions developed at or before age 60 years and their age of onset are important for predicting...
IBD Activity May Increase Risk for Clostridioides Difficile Infection
WEDNESDAY, March 5, 2025 -- For patients with inflammatory bowel disease (IBD), risk factors associated with Clostridioides difficile infection (CDI) include recent diagnosis...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.